The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab

American Journal of Hematology

Volumn 82, Issue 9, 2007, Pages 846-848

  Kuwana, Masataka ^a   Iki, S ^b   Urabe, A ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kanto Teishin Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; DEXAMETHASONE; FIBRINOGEN RECEPTOR ANTAGONIST; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PREDNISOLONE; RITUXIMAB; VINCRISTINE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

AGED; ANTIBODY PRODUCING CELL; ARTICLE; CASE REPORT; DRUG RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; PLASMA CELL; PRIORITY JOURNAL; BLOOD; IMMUNOLOGY; METABOLISM; THROMBOCYTE COUNT; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; PLASMA CELLS; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TREATMENT OUTCOME;

EID: 35748974876     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20951     Document Type: Article

References (12)

1. Cines DB, Blanchette V. Immune thrombocytopenic purpura. New Engl J Med 2002;346:995-1008.
2. George J. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006;4:1664-1672.
3. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-2466.
4. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125:232-239.
5. Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006;107:2639-2642.
6. Peñalver FJ, Jiménez-Yuste V, Almagro M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: An effective and safe therapeutic alternative in refractory patients. Ann Hematol 2006;85:400-406.
7. Herishanu Y. Rituximab-induced serum sickness. Am J Hematol 2002;70:329.
8. Maeda T, Yamada Y, Tawara M, et al. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. Int J Hematol 2001;74:70-75.
9. Hoyer BF, Manz RA, Radbruch A, Hiepe F. Long-lived plasma cells and their contribution to autoimmunity. Ann NY Acad Sci 2005;1050:124-133.
10. Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen is a primary site for activation of glycoprotein IIb-IIIa-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 2002;168:3675-3682.
11. Kuwana M, Okazaki Y, Kaburaki J, Ikeda Y. Detection of circulating B cells secreting platelet-specific autoantibody is a sensitive and specific test for the diagnosis of autoimmune thrombocytopenia. Am J Med 2003;114:322-325.
12. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994,83:435-445.